PPI - Radically Pragmatic
  • Donate
Skip to content
  • Home
  • About
    • About Us
    • Locations
    • Careers
  • People
  • Projects
  • Our Work
  • Events
  • Donate

Our Work

The Problem with PBMs

  • October 3, 2018
  • Arielle Kane
Download PDF

Carl Icahn, the billionaire businessman and investor, recently advised shareholders to reject Cigna’s proposed $67 billion acquisition of the pharmacy benefit manager (PBM) Express Scripts. He says that a reckoning is coming for PBMs and that the price grossly exaggerated their value as “over-earning middle men.”

In 2016, PBMs made $23 billion in gross profits – with most having never touched a drug. They don’t make them, they don’t distribute them and they don’t sell them. So what do PBMs do, and why is there so much misunderstanding about their value?

Because of the structure of PBMs, they create perverse incentives for drug makers to price drugs high. A flat fee structure, greater clarity of drug costs, and increased competition would help increase transparency, align incentives, and reduce costs for the pharmaceutical sector.

 

Related Work

Blog  |  May 21, 2025

Republicans Surrender the War on Cancer

  • Alix Ware
Blog  |  May 19, 2025

The Media’s Misguided Coverage of Smoke-Free Nicotine Products

  • Lindsay Mark Lewis
Blog  |  December 9, 2024

Why the U.S. Senate Should Reject RFK Jr.

  • Daphne Hansell
Press Release  |  October 21, 2024

New PPI Report Proposes Solutions to Reduce Health Care Costs for Working Americans

  • Erin Delaney
Publication  |  October 21, 2024

A Comprehensive Plan to Lower Health Costs Without Reducing Coverage

  • Erin Delaney
Blog  |  September 12, 2024

Harris’ Pledge: Affordable Health Care and Reproductive Rights

  • Erin Delaney
  • Never miss an update:

  • Subscribe to our newsletter
PPI Logo
  • Twitter
  • LinkedIn
  • Facebook
  • Donate
  • Careers
  • © 2025 Progressive Policy Institute. All Rights Reserved.
  • |
  • Privacy Policy
  • |
  • Privacy Settings